Payment overview · 2025
General Payments
$47.50
2 reported records · 2 companies
Healthcare provider profile · identity verified
Robert L Buckingham, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OJAI, CA · NPI 1023147675
Verified facts
What the public records show
CMS Open Payments records show Robert L Buckingham, MD received $47.50 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.19 | 57.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.31 | 42.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $47.50 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
236 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 70 |
| Potassium Chloride | Potassium Chloride | 366 | 61 |
| Losartan Potassium | Losartan Potassium | 351 | 74 |
| Xarelto | Rivaroxaban | 351 | 34 |
| Mirtazapine | Mirtazapine | 347 | 53 |
| Metformin Hcl | Metformin Hcl | 339 | 60 |
| Omeprazole | Omeprazole | 331 | 58 |
| Eliquis | Apixaban | 328 | 41 |
| Furosemide | Furosemide | 325 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 63 |
| Gabapentin | Gabapentin | 298 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 262 | 42 |
| Jardiance | Empagliflozin | 236 | 35 |
| Fenofibrate | Fenofibrate Nanocrystallized | 227 | 34 |
| Trazodone Hcl | Trazodone Hcl | 204 | 46 |
| Famotidine | Famotidine | 199 | 38 |
| Levetiracetam | Levetiracetam | 197 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 40 |
| Lorazepam | Lorazepam | 176 | 33 |
| Lisinopril | Lisinopril | 166 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 163 | 28 |
| Alendronate Sodium | Alendronate Sodium | 160 | 37 |
| Sertraline Hcl | Sertraline Hcl | 155 | 24 |
| Finasteride | Finasteride | 149 | 26 |
| Colchicine | Colchicine | 142 | 50 |
| Nifedipine Er | Nifedipine | 137 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 25 |
| Carvedilol | Carvedilol | 133 | 26 |
| Divalproex Sodium | Divalproex Sodium | 130 | 17 |
| Januvia | Sitagliptin Phosphate | 121 | 11 |
| Bumetanide | Bumetanide | 112 | 24 |
| Clonazepam | Clonazepam | 112 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 112 | 29 |
| Methenamine Hippurate | Methenamine Hippurate | 106 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 99 | 14 |
| Clonidine Hcl | Clonidine Hcl | 98 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 15 |
| Spironolactone | Spironolactone | 89 | 18 |
| Digoxin | Digoxin | 87 | 19 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 85 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 84 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 82 | 12 |
| Benazepril Hcl | Benazepril Hcl | 79 | 14 |
| Allopurinol | Allopurinol | 78 | 13 |
| Baclofen | Baclofen | 78 | 13 |
| Memantine Hcl | Memantine Hcl | 77 | 19 |
| Glimepiride | Glimepiride | 75 | 16 |
| Prednisone | Prednisone | 75 | 34 |
| Tramadol Hcl | Tramadol Hcl | 73 | 15 |
| Valsartan | Valsartan | 73 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Alprazolam | Alprazolam | 65 | 17 |
| Scopolamine | Scopolamine | 63 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 61 | 14 |
| Kapspargo Sprinkle | Metoprolol Succinate | 59 | 14 |
| Lactulose | Lactulose | 59 | 21 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 58 | 20 |
| Ibuprofen | Ibuprofen | 58 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 23 |
| Cephalexin | Cephalexin | 57 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 25 |
| Lacosamide | Lacosamide | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 54 | suppressed |
| Rybelsus | Semaglutide | 54 | 14 |
| Progesterone | Progesterone, Micronized | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 14 |
| Carbamazepine | Carbamazepine | 50 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Humalog | Insulin Lispro | 47 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Methadone Hcl | Methadone Hcl | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Humulin R | Insulin Regular, Human | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 22 |
| Budesonide | Budesonide | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 36 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | 11 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | 12 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 11 |
| Primidone | Primidone | 32 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | 13 |
| Permethrin | Permethrin | 31 | 22 |
| Risperidone | Risperidone | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 19 |
| Simvastatin | Simvastatin | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Minoxidil | Minoxidil | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 14 |
| Phenytoin | Phenytoin | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47.50 · 2 records | AstraZeneca Pharmaceuticals LP | FARXIGA, MOUNJARO, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error